• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Data transparency regarding medical devices - the position of the medical device industry].

作者信息

Soskuty Gabriela

机构信息

B. Braun Melsungen AG, Melsungen.

出版信息

Z Evid Fortbild Qual Gesundhwes. 2011;105(3):189-93. doi: 10.1016/j.zefq.2011.03.002. Epub 2011 Apr 2.

DOI:10.1016/j.zefq.2011.03.002
PMID:21530908
Abstract

The medical device industry, strongly dominated by medium-sized firms, has significant growth potential and a high number of job opportunities with 170,000 employees in more than 11,000 companies. Approximately one third of the business volume is achieved with innovative products that are less than three years old. The safety, quality and efficiency of the products is tested and approved by CE certification. Due to the heterogeneous field of devices, however, evidence requirements must be differentiated according to the type of device in question. Transparency is as important as the type of evidence, and industry is well aware of the significance of transparency for credibility in the market. Industry believes that all the stakeholders affected must collaborate to define the evidence requirements and decide which data are necessary to assess the benefits of a technology. Before a consistent level of transparency can be achieved, however, it is crucial to jointly develop a framework of requirements including invasiveness, risk potential, patient-relevant endpoints and intended use of the technology, as well as the data source. Transparency is a process that can only be achieved if all stakeholders cooperate successfully. Also, it is important to keep in mind that the development of study designs and reliable evidence needs time. In the interest of all patients it is essential to maintain an innovation-friendly climate in Germany.

摘要

相似文献

1
[Data transparency regarding medical devices - the position of the medical device industry].
Z Evid Fortbild Qual Gesundhwes. 2011;105(3):189-93. doi: 10.1016/j.zefq.2011.03.002. Epub 2011 Apr 2.
2
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
3
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
4
[Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].[欧洲创新型高风险医疗器械的引入:临床疗效和安全性有保障吗?]
Rev Epidemiol Sante Publique. 2013 Apr;61(2):105-10. doi: 10.1016/j.respe.2012.08.004. Epub 2013 Mar 7.
5
[Medical innovations in the area of conflict between certification and allowance].[认证与津贴冲突领域的医学创新]
Dtsch Med Wochenschr. 2010 Oct;135(42):2088-92. doi: 10.1055/s-0030-1267484. Epub 2010 Oct 12.
6
[Options for a future-oriented innovation policy in the medical devices industry].[医疗器械行业面向未来的创新政策选项]
Z Evid Fortbild Qual Gesundhwes. 2010;104(10):709-14. doi: 10.1016/j.zefq.2010.08.004. Epub 2010 Oct 12.
7
[Clinical trials with medical devices: lack of quality illustrated for faecal incontinence].[医疗器械的临床试验:大便失禁相关研究质量欠佳]
Zentralbl Chir. 2012 Aug;137(4):380-4. doi: 10.1055/s-0031-1271549. Epub 2011 Jul 7.
8
[Medical doctors driving technological innovation: questions about and innovation management approaches to incentive structures for lead users].[推动技术创新的医生:关于领先用户激励机制的问题及创新管理方法]
Z Evid Fortbild Qual Gesundhwes. 2010;104(10):721-6. doi: 10.1016/j.zefq.2010.09.039. Epub 2010 Nov 3.
9
Medical devices; refurbishers, rebuilders, reconditioners, servicers, and "as is" remarketers of medical devices; review and revision of compliance policy guides and regulatory requirements; request for comments and information--FDA. Advance notice of proposed rulemaking.医疗器械;医疗器械翻新商、重建商、修复商、服务商以及“按现状”再销售商;合规政策指南和监管要求的审查与修订;征求意见和信息——美国食品药品监督管理局。拟议规则制定预先通知。
Fed Regist. 1997 Dec 23;62(246):67011-3.
10
Regulation of medical devices in the European Union.欧盟医疗器械监管
J Leg Med. 2000 Dec;21(4):537-56. doi: 10.1080/019476400455799.